Search Results for: cnsp

CNS Pharmaceuticals is a pre-clinical-stage developer of novel brain cancer-fighting drugs, including its lead candidate Berubicin The company is working to build on promising results from a 2006 Phase I trial, which provided 44 percent of its limited patient pool with clinically significant improvement in disease stability and one patient with a durable complete response … Continue reading “CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Takes Another Step Closer to Q1 Launch of Brain Cancer Drug Trial”

Clinical-stage biotech developer CNS Pharmaceuticals is working to demonstrate the potential effectiveness of its novel drug, Berubicin, in treating aggressive and rare brain cancer glioblastoma multiforme (“GBM”) CNS expects to launch Phase II trials of Berubicin later this year or in Q1 of 2021, building on promising results shown in initial trials One patient in … Continue reading “CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Partnership with Imaging Specialists IAG Gives Tech Boost to Upcoming Brain Cancer Drug Trials”

Pivotal Phase 2 Berubicin trial expected to commence in Q1 2021 following planned IND submission in Q4 2020 CNS Pharmaceuticals also plans to begin pre-clinical work on Berubicin in connection with treatment for lymphomas, pancreatic, and ovarian cancers Brain tumor drug therapeutics market expected to reach $3.4 billion by 2025 CNS Pharmaceuticals (NASDAQ: CNSP), a … Continue reading “CNS Pharmaceuticals, Inc. (CNSP) Expands Scientific Advisory Board with Leading Neuro-Oncology Expert, Dr. Patrick Wen, M.D.”

CNS Pharmaceuticals’ lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and currently incurable form of brain cancer. In a Phase I clinical trial of Berubicin in malignant brain tumors, 44% of patients experienced a statistically significant improvement in clinical benefit. In preclinical studies, the company’s second drug candidate, … Continue reading “CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is “One to Watch””

CNS Pharmaceuticals is a clinical-stage biotechnology company developing therapies to combat aggressive cancers of the brain and central nervous system The company will be applying for approval to launch Phase II trials in the first quarter of 2021 for its leading drug candidate, Berubicin, which targets glioblastoma multiforme (“GBM”) brain cancer CNS Pharmaceuticals CEO addressed … Continue reading “CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Mines Investment-building Opportunity for Brain Tumor-Targeting Drug Candidate at Annual Conference”